Imprint
Combined legal notice (provider identification) under the Telemediengesetz (TMG, Electronic Information and Communication Services Act) and the Staatsvertrag für Rundfunk und Telemedien (RStV, State Treaty on Broadcasting and Electronic Information and Communication Services)
Medigene AG, represented by Chief Executive Officer Dr. Selwyn Ho, is the provider and therefore responsible for the commercial and business website within the meaning of Section 5 of the Telemediengesetz in its function as the core act under the Elektronischer-Geschäftsverkehr-Vereinheitlichungsgesetz (ElGVG, E-Commerce Standardization Act) and the Gesetz zur Regelung der Rahmenbedingungen für Informations- und Kommunikationsdienste (IuKDG, Act Regulating the Framework Conditions for Information and Communication Services).
This website is brought to you by
Medigene AG
Lochhamer Str. 11
82152 Planegg/Martinsried
Germany
Telephone: +49 89 200033-0
Fax: +49 89 200033-2920
Email: info(at)medigene.com
Web: medigene.com
Registered office of Medigene AG | 82152 Planegg/Martinsried, Germany |
District Court of Munich, HRB 115761 | |
Legal form | Joint stock company (AG) |
Governing law | Law of the Federal Republic of Germany (FRG) |
Munich revenue office VAT number | DE 167 014 708 |
Executive Management Board members with power of representation | Dr. Selwyn Ho, Prof. Dr. Dolores J. Schendel |
Responsible Chamber
Chamber of Industry and Commerce for Munich and Upper Bavaria
Balanstraβe 55 – 59
81541 Munich
Germany
Telephone: +49 89 5116-0
Fax: +49 89 5116-1306
Email: ihkmail(at)muenchen.ihk.de
Web: www.muenchen.ihk.de
Information regarding the settlement of online disputes pursuant to Article 14 (1) ODR-VO (Online Dispute Resolution Regulation)
The European Commission makes available a platform for online dispute resolution at http://ec.europa.eu/consumers/odr. This platform is designed to be a contact point for out-of-court settlement of disputes regarding contractual obligations arising from online sale and purchase agreements.
We are neither obliged nor willing to participate in dispute resolution before a consumer mediation service.
Responsible for editorial content pursuant to Section 18 (2) Medienstaatsvertrag (MStV)
Investor Relations & Corporate Communications
E-Mail: investor(at)medigene.com
External data protection officer pursuant to Article 37 DSGVO in conjunction with § 38 Abs. 1 BDSG-neu (BDSG, German Data Protection Act)
Sven Lenz
Deutsche Datenschutzkanzlei – Datenschutzkanzlei Lenz GmbH & Co. KG
Bahnhofstr. 50
87435 Kempten
Germany
E-Mail: datenschutz(at)medigene.com
Web: www.deutsche-datenschutzkanzlei.de
Features of Medigene AG’s services
Direct or indirect activities related to the development and marketing of, in particular, molecular biology technologies, methods and products in the sector of drugs, active pharmaceutical ingredients and the relevant intermediate products, as well as delivery of associated services. The Company may pursue its business purpose itself or via subsidiaries and affiliated companies.
Liability
Medigene AG may change all or parts of this website anytime without prior announcement at its discretion, or close it down, without assuming liability. Creating links to third party websites (hyperlinks) does not mean that Medigene AG is responsible for such websites or their content. Furthermore, Medigene AG is not responsible for the availability of such websites or their content.
This imprint (legal notice) and the privacy policy were prepared by
Deutsche Datenschutzkanzlei, Munich Data Protection Office – www.deutsche-datenschutzkanzlei.de
Copyright
All rights reserved. Text, pictures and graphics as well as their formatting on the website are subject to copyright law and other protective laws. The content of this website must not be copied, disseminated, changed or made available to third parties for commercial purposes.
Copyright – picture sources
Oliver Tjaden, Matthias Tunger, Shutterstock, Medigene AG
NB: Allgemeines Gleichbehandlungsgesetz (AGG, General Act on Equal Treatment Act)
In order to facilitate readability, gender-neutral language is used. The relevant terms apply to both genders in line with equal treatment.